BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CFO Brian C. Stephenson sold 4,156 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total value of $93,135.96. Following the completion of the transaction, the chief financial officer now directly owns 93,758 shares of the company's stock, valued at $2,101,116.78. This trade represents a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
BridgeBio Pharma Stock Up 2.2 %
BBIO stock opened at $23.04 on Thursday. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $44.32. The firm has a 50-day moving average of $25.09 and a two-hundred day moving average of $26.31.
Analyst Ratings Changes
A number of brokerages have recently commented on BBIO. HC Wainwright reissued a "buy" rating and set a $43.00 price target on shares of BridgeBio Pharma in a report on Friday, October 25th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $70.00 price target on shares of BridgeBio Pharma in a research note on Monday, September 16th. Leerink Partners lowered their price objective on shares of BridgeBio Pharma from $47.00 to $46.00 and set an "outperform" rating on the stock in a research note on Thursday, October 17th. Scotiabank upped their target price on BridgeBio Pharma from $44.00 to $45.00 and gave the stock a "sector outperform" rating in a research report on Friday, November 15th. Finally, Oppenheimer began coverage on BridgeBio Pharma in a research report on Thursday, October 3rd. They set a "market perform" rating on the stock. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $47.57.
We recommended Nvidia in 2016, now we’re recommending this…
From Porter & Company | Ad
The AI boom is just getting started.
And the real wealth has still to be made…
You must read this new presentation from Porter Stansberry.
Read Our Latest Stock Analysis on BridgeBio Pharma
Institutional Investors Weigh In On BridgeBio Pharma
Several hedge funds have recently made changes to their positions in BBIO. Vanguard Group Inc. raised its stake in BridgeBio Pharma by 3.3% during the 1st quarter. Vanguard Group Inc. now owns 13,222,126 shares of the company's stock valued at $408,828,000 after purchasing an additional 421,832 shares during the period. Janus Henderson Group PLC raised its position in BridgeBio Pharma by 11.7% during the third quarter. Janus Henderson Group PLC now owns 4,818,012 shares of the company's stock valued at $122,658,000 after buying an additional 505,481 shares during the period. Frazier Life Sciences Management L.P. lifted its stake in BridgeBio Pharma by 3.5% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 3,760,457 shares of the company's stock worth $95,741,000 after acquiring an additional 127,853 shares in the last quarter. Geode Capital Management LLC boosted its position in BridgeBio Pharma by 3.8% during the 3rd quarter. Geode Capital Management LLC now owns 3,413,949 shares of the company's stock worth $86,936,000 after acquiring an additional 123,540 shares during the period. Finally, Capital Research Global Investors grew its stake in BridgeBio Pharma by 101.1% during the 1st quarter. Capital Research Global Investors now owns 2,212,085 shares of the company's stock valued at $68,398,000 after acquiring an additional 1,111,975 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company's stock.
BridgeBio Pharma Company Profile
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
